Evidence map›Paper›PMID 38780898›Full record

ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2024

Molecular Subtypes of High-Grade Serous Ovarian Cancer across Racial Groups and Gene Expression Platforms.

Natalie R Davidson, Mollie E Barnard, Ariel A Hippen, Amy Campbell, Courtney E Johnson, Gregory P Way, Brian K Dalley, Andrew Berchuck, Lucas A Salas, Lauren C Peres and 4 more

Abstract read
In one paragraph

Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Article
  2. The KPROCS Study: A Real-World and Research Resource to Investigate Multilevel Determinants of Ovarian Cancer Treatment and Survival.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Homologous Recombination Deficiency and Survival in Ovarian High-Grade Serous Carcinoma by Self-Reported Race.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025
    Article
  7. Article
  8. Article
  9. An Analytic Pipeline to Obtain Reliable Genetic Ancestry Estimates from Tumor-Derived RNA Sequencing Data.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025
    Article
  10. Review
  11. Article
  12. Patterns of Associations with Epidemiologic Factors by High-Grade Serous Ovarian Cancer Gene Expression Subtypes.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025
    Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Natalie R Davidson *Department of Biomedical Informatics, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado.ORCID 0000-0002-1745-8072
Mollie E Barnard *Department of Population Health Sciences at the Spencer Fox Eccles School of Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.ORCID 0000-0002-4843-4655
Ariel A HippenDepartment of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.ORCID 0000-0001-9336-6543
Amy CampbellDepartment of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.ORCID 0000-0003-3676-2253
Courtney E JohnsonDepartment of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia.ORCID 0000-0003-4980-3499
Gregory P WayDepartment of Biomedical Informatics, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado.ORCID 0000-0002-0503-9348
Brian K DalleyHuntsman Cancer Institute, University of Utah, Salt Lake City, Utah.ORCID 0009-0003-9774-5200
Andrew BerchuckDepartment of Obstetrics and Gynecology, Duke University, Durham, North Carolina.ORCID 0000-0002-1940-1467
Lucas A SalasDepartment of Epidemiology, Geisel School of Medicine, Dartmouth College, Hanover, New Hampshire.ORCID 0000-0002-2279-4097
Lauren C PeresDepartment of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.ORCID 0000-0002-6620-8600
Jeffrey R MarksDepartment of Surgery, Duke University School of Medicine, Durham, North Carolina.ORCID 0000-0002-2054-5468
Joellen M Schildkraut *Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia.ORCID 0000-0002-0990-9339
Casey S Greene *Department of Biomedical Informatics, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado.ORCID 0000-0001-8713-9213
Jennifer A Doherty *Department of Population Health Sciences at the Spencer Fox Eccles School of Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.ORCID 0000-0002-1454-8187

Funding

UTAH REGIONAL CANCER CENTERP30CA042014 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI KATHARINE S ULLMAN · 1986 to 2026
$72.6M
Epidemiology of Ovarian Cancer in African-American WomenR01CA142081 · NCI · UNIVERSITY OF VIRGINIA · PI SCHILDKRAUT, JOELLEN M. · 2010 to 2015
$10.6M
The Molecular Epidemiology Of Ovarian CancerR01CA076016 · NCI · DUKE UNIVERSITY · PI SCHILDKRAUT, JOELLEN M. · 1998 to 2010
$6.2M
Discovery of Novel Rare Variants as Ovarian Cancer Susceptibility FactorsR01CA188943 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HILDEBRANDT, MICHELLE A T, HUFF, CHAD DANIEL · 2015 to 2019
$5.5M
Characterization of high-grade serous ovarian cancer subtypes via single-cell profilingR01CA237170 · NCI · UNIVERSITY OF PENNSYLVANIA · PI DOHERTY, JENNIFER A., GREENE, CASEY S · 2019 to 2024
$3.0M
Characterizing Molecular Subtypes of Ovarian Cancer in African-American WomenR01CA200854 · NCI · UNIVERSITY OF UTAH · PI DOHERTY, JENNIFER A., SCHILDKRAUT, JOELLEN M. · 2016 to 2021
$2.8M
The Role of Inflammation in the Racial Disparities in Ovarian Cancer SurvivalR00CA218681 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI PERES, LAUREN COLE · 2018 to 2020
$722k
Inflammation and gynecologic cancer: the role of prostaglandins in ovarian cancerK00CA212222 · NCI · UNIVERSITY OF UTAH · PI BARNARD, MOLLIE ELYSE · 2018 to 2021
$415k
National Cancer Institute (NCI) P30CA042014National Cancer Institute (NCI) R00CA218681NCI NIH HHS K00 CA212222NCI NIH HHS P30 CA042014NCI NIH HHS R00 CA218681NCI NIH HHS R01 CA076016NCI NIH HHS R01 CA142081NCI NIH HHS R01 CA188943NCI NIH HHS R01 CA200854NCI NIH HHS R01 CA237170
6 · The paper itself

Abstract

backgroundHigh-grade serous carcinoma (HGSC) gene expression subtypes are associated with differential survival. We characterized HGSC gene expression in Black individuals and considered whether gene expression differences by self-identified race may contribute to poorer HGSC survival among Black versus White individuals.

methodsWe included newly generated RNA sequencing data from Black and White individuals and array-based genotyping data from four existing studies of White and Japanese individuals. We used K-means clustering, a method with no predefined number of clusters or dataset-specific features, to assign subtypes. Cluster- and dataset-specific gene expression patterns were summarized by moderated t-scores. We compared cluster-specific gene expression patterns across datasets by calculating the correlation between the summarized vectors of moderated t-scores. After mapping to The Cancer Genome Atlas-derived HGSC subtypes, we used Cox proportional hazards models to estimate subtype-specific survival by dataset.

resultsCluster-specific gene expression was similar across gene expression platforms and racial groups. Comparing the Black population with the White and Japanese populations, the immunoreactive subtype was more common (39% vs. 23%-28%) and the differentiated subtype was less common (7% vs. 22%-31%). Patterns of subtype-specific survival were similar between the Black and White populations with RNA sequencing data; compared with mesenchymal cases, the risk of death was similar for proliferative and differentiated cases and suggestively lower for immunoreactive cases [Black population HR = 0.79 (0.55, 1.13); White population HR = 0.86 (0.62, 1.19)].

conclusionsAlthough the prevalence of HGSC subtypes varied by race, subtype-specific survival was similar. IMPACT: HGSC subtypes can be consistently assigned across platforms and self-identified racial groups.

Indexed as

Cystadenocarcinoma, SerousOvarian NeoplasmsAgedBlack or African AmericanFemaleHumansMiddle AgedNeoplasm GradingWhite

Identifiers

PMID38780898
PMCPMC11294000

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.